Shanghai Meiji Health Science and Technology Co., Ltd

计划入组 95 人 · 首次发布于 2020 年 12 月 3 日

A multicenter, randomized, double-blind, positive-controlled clinical trial to evaluate the efficacy and safety of Compound Yinhua Jiedu Granule in the treatment of influenza (wind-heat syndrome)

Online Training for the Reconstitution of Fosun/BioNTech

计划入组 385 人 · 首次发布于 2022 年 4 月 8 日

Recombinant hirudin

Factor X activator(Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)

Tetanus vaccines(Shanghai Fosun Pharmaceutical)

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

China

Shanghai Yingli Pharmaceutical Co., Ltd

China

Shanghai HEP Pharmaceutical CO., Ltd

China

Fosun Pharma's Innovative Drug Receives Registration Acceptance in China

Accro Bioscience Secures China Regulatory Clearance for Vitiligo Trial

Accro Bioscience Announces NMPA Clearance for Phase II/III Trial of AC-201, a Selective TYK2/JAK1 Inhibitor for Non-Segmental Vitiligo